Abstract: A method of treating central nervous system (CNS) diseases in a subject is provided. The method comprises administering to the subject a therapeutically effective amount of Antcin H and/or its derivatives. The novel use of Antcin H and/or its derivatives are also provided.

Abstract: The present disclosure disclosed herein a recombinant antibody or the antigen-binding fragment thereof which specifically binds GM2-activator protein (GM2AP). The recombinant antibody or the antigen-binding fragment thereof comprises a light chain variable region (LCVR) comprising three light chain complementary determining regions (LCDR1-3) amino acid sequences and a heavy chain variable region (HCVR) comprising three heavy chain complementary determining regions (HCDR1-3) set forth in the sequences disclosed in the embodiments of the present application. Polynucleotides encoding the same, vectors, host cells, kits and methods for detecting GM2AP and methods for inducing these recombinant antibodies or the antigen-binding fragment thereof are also provided.

Abstract: Disclosed herein are a method of treating, reducing the risk of, preventing, or alleviating angiotensin converting enzyme 2 (ACE-2) associated state in a subject, comprising administering to the subject a therapeutically effective amount of Antrodia cinnamomea extract (Ant-Ex) or fraction 3 thereof (AE-F03). Also provided herein are uses of Ant-Ex or AE-F03 in reducing ACE-2 expression and manufacturing a drug or a food supplement for treating, reducing the risk of, preventing, or alleviating ACE-2 associated state.

Abstract: The present disclosure disclosed herein a recombinant antibody or the antigen-binding fragment thereof which specifically binds GM2-activator protein (GM2AP). The recombinant antibody or the antigen-binding fragment thereof comprises a light chain variable region (LCVR) comprising three light chain complementary determining regions (LCDR1-3) amino acid sequences and a heavy chain variable region (HCVR) comprising three heavy chain complementary determining regions (HCDR1-3) set forth in the sequences disclosed in the embodiments of the present application. Polynucleotides encoding the same, vectors, host cells, kits and methods for detecting GM2AP and methods for inducing these recombinant antibodies or the antigen-binding fragment thereof are also provided.

Abstract: The present invention relates to a lung cancer biomarker for diagnosing early stage lung cancers or predicting prognosis of lung cancers, which comprises a GM2AP protein. The present invention also relates to a method for diagnosing early stage lung cancers or predicting prognosis of lung cancers in vitro by detection of the biomarker.

Abstract: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.

Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: The present invention relates to a lung cancer biomarker for diagnosing early stage lung cancers or predicting prognosis of lung cancers, which comprises a GM2AP protein. The present invention also relates to a method for diagnosing early stage lung cancers or predicting prognosis of lung cancers in vitro by detection of the biomarker.

Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.

Abstract: The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage/lymphocyte infiltration, etc.

Abstract: The present invention relates to a pharmaceutical composition for treating liver diseases, comprising a miRNA mimic containing a single strand RNA molecule of hsa-miR-21-3p (SEQ ID No: 35). The miRNA mimic of the present invention can be used to treat liver diseases through regulating the expression of methionine adenosyltransferase 2A and 2B (MAT2A and MAT2B), acetyl-CoA carboxylase 1 and 2 (ACACA and ACACB), diglyceride acyltransferase 2 (DGAT2), and so on. In addition, the present invention also relates to a method for reducing the expression of the above-mentioned enzymes.

Abstract: Method of treating hypertension with a trans-aconitic acid containing composition (e.g., a water extract derived from a monocotyledon plant).

Abstract: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.

Abstract: A method of preparing porous carbon materials using agriculture wastes derived from plants.

Abstract: Method of treating hypertension with a trans-aconitic acid containing composition (e.g., a water extract derived from a monocotyledon plant).

Abstract: The present invention provides methods of modulating an immune response in an organism by administering medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum.

Abstract: The present invention provides methods of modulating an immune response in an organism by administering medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum.

Abstract: The present invention relates to a method for immuno-modulation in an organism by using a protein extract from a monocotyledon plant. The present invention also relates to a method for inhibiting nitrite production or anti-oxidation activity in an organism by using an organic extract from a monocotyledon plant. The present invention also relates to a method for regulating uric acid in an organism by using 6-aminopurine analogues.

Abstract: The present invention provides medicinally active extracts and fractions, and a method for preparing the same by extracting and fractioning constituents from the tissue of components of Ganoderma lucidum. These active extracts and fractions are useful for inhibiting tumor growth, modulating immune response, and increasing hematopoietic activity.